3-(4,5-Dihydroimidazol-1-yl)thiolane 1,1-dioxide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫杂环戊烷
• 英文名称: 3-(4,5-Dihydroimidazol-1-yl)thiolane 1,1-dioxide
• 英文别名: 3-(4,5-dihydroimidazol-1-yl)thiolane 1,1-dioxide
• 化学式: C₇H₁₂N₂O₂S
• 分子量: 188.25
• InChiKey: KXKOQISONVBGHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  58.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• PRODRUGS OF PHENOLIC TRPV1 AGONISTS
  申请人：Concentric Analgesics, Inc.

  公开号：EP3223805B1

  公开（公告）日：2021-02-24
• [EN] USE OF CRAC CHANNEL INHIBITORS FOR THE TREATMENT OF STROKE AND TRAUMATIC BRAIN INJURY<br/>[FR] UTILISATION D'INHIBITEURS DU CANAL CRAC POUR LE TRAITEMENT D'UN ACCIDENT VASCULAIRE CÉRÉBRAL ET D'UNE LÉSION CÉRÉBRALE TRAUMATIQUE
  申请人：CALCIMEDICA INC

  公开号：WO2017027400A1

  公开（公告）日：2017-02-16

  Described herein are methods of treatment of stroke and traumatic brain injury comprising administration of a CRAC channel inhibitor.
• [EN] PEGYLATED PRODRUGS OF PHENOLIC TRPV1 AGONISTS<br/>[FR] PROMÉDICAMENTS PEGYLÉS D'AGONISTES DU TRPV1 PHÉNOLIQUE
  申请人：CONCENTRIC ANALGESICS INC

  公开号：WO2020023794A1

  公开（公告）日：2020-01-30

  Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.
• [EN] METHODS FOR TREATING CHOLESTASIS<br/>[FR] PROCÉDÉS DE TRAITEMENT DE LA CHOLESTASE
  申请人：MIRUM PHARMACEUTICALS INC

  公开号：WO2020167958A1

  公开（公告）日：2020-08-20

  Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg/kg/day.
• [EN] GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY<br/>[FR] RÉPONSE DÉPENDANT DU GÉNOTYPE ET DE LA DOSE À UN ASBTI CHEZ DES PATIENTS AYANT UNE DÉFICIENCE DE POMPE D'EXPORTATION DE SEL BILIAIRE
  申请人：MIRUM PHARMACEUTICALS INC

  公开号：WO2020167964A1

  公开（公告）日：2020-08-20

  Provided herein are methods for treating or ameliorating cholestatic liver disease in a subject in need thereof. The methods include administering an Apical Sodium-dependent Bile Acid Transport Inhibitor (ASBTI) to the subject. The methods include determining a genotype of the subject and predicting subject response to the ASBTI administration based upon the genotype. The methods further include determining, adjusting, or modulating a dose of the ASBTI administered to the subject based upon the genotype or upon measurements of clinically relevant disease parameters.